TIMEPIDIUM

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H22NOS2
Molecular Weight	320.493
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	1

SHOW SMILES / InChI

Structure Search

SMILES

COC1CC(C[N+](C)(C)C1)=C(C2=CC=CS2)C3=CC=CS3

InChI

InChIKey=PDYOTUCJOLELJU-UHFFFAOYSA-N

InChI=1S/C17H22NOS2/c1-18(2)11-13(10-14(12-18)19-3)17(15-6-4-8-20-15)16-7-5-9-21-16/h4-9,14H,10-12H2,1-3H3/q+1

HIDE SMILES / InChI

Molecular Formula	C17H22NOS2
Molecular Weight	320.493
Charge	1
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7262709 | https://www.ncbi.nlm.nih.gov/pubmed/10374898

Timepidium bromide is a quaternary ammonium antimuscarinic used for the symptomatic treatment of visceral spasms. It is a muscarinic antagonist.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Muscarinic acetylcholine receptor M1 169 Target ID: CHEMBL216 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898	Antagonist 2778	34.0 nM [Ki]
Muscarinic acetylcholine receptor M2 121 Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898	Antagonist 2778	7.7 nM [Ki]
Muscarinic acetylcholine receptor M3 159 Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898	Antagonist 2778	31.0 nM [Ki]
Muscarinic acetylcholine receptor M4 86 Target ID: CHEMBL1821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898	Antagonist 2778	18.0 nM [Ki]
Muscarinic acetylcholine receptor M5 62 Target ID: CHEMBL2035 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10374898	Antagonist 2778	11.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Visceral spasms 6 Sources: http://en.pharmacodia.com/web/drug/1_11398.html https://www.ncbi.nlm.nih.gov/pubmed/700518	Primary		Approved 8429	Sesden Approved Use Visceral spasms

PubMed

Title	Date	PubMed
Eosinophilic pustular folliculitis induced by allopurinol and timepidium bromide.	2002	12361147
Multiple granulomatous inflammation in the minor salivary glands: a proposed new entity, allergic granulomatous sialadenitis.	2004 Nov	15533228
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443

Patents

Sample Use Guides

In Vivo Use Guide

Adult Dosage: 30mg x 3 times a day.

Route of Administration: Oral

In Vitro Use Guide

Timepidium inhibited dose-dependently the contraction of isolated guinea pig gallbladder evoked by stimulation at 5 Hz. The mean dose producing a 50 % decrease in the electrically induced contraction (ID50 value) was 2.4 x 10(-8) g/ml. Timepidium (10(-6) g/ml) also inhibited, for the most part, the contraction induced by stimulation at 30 Hz.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:30:53 GMT 2023` Edited by `admin` on `Fri Dec 15 16:30:53 GMT 2023`
Record UNII	C1WS2XH3K4
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TIMEPIDIUM

Common Name

English

PIPERIDINIUM, 3-(DI-2-THIENYLMETHYLENE)-5-METHOXY-1,1-DIMETHYL-

Systematic Name

English

TIMEPIDIUM ION

Common Name

English

3-(DI-2-THIENYLMETHYLENE)-5-METHOXY-1,1-DIMETHYL-PIPERIDINIUM

Systematic Name

English

TIMEPIDIUM CATION

Common Name

English

Timepidium [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29704